carbidopa has been researched along with cytarabine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Luque, FA; Petruska, P; Selhorst, JB | 1 |
Kulkantrakorn, K; Petruska, PJ; Selhorst, JB | 1 |
Bojko, A; Chutorian, AM; Edelberg, D; Frucht, S; Heier, L; Nygaard, T | 1 |
1 review(s) available for carbidopa and cytarabine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for carbidopa and cytarabine
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Parkinsonism induced by high-dose cytosine arabinoside.
Topics: Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1987 |
Cytosine arabinoside and amphotericin B-induced parkinsonism.
Topics: Amphotericin B; Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Lung Diseases; Middle Aged; Parkinson Disease, Secondary | 1996 |
Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment.
Topics: Antimetabolites, Antineoplastic; Antiparkinson Agents; Carbidopa; Child; Cytarabine; Humans; Levodopa; Male; Parkinson Disease, Secondary | 2003 |